The new formula features a quartet of active ingredients: 4% glycolic, 3% phytic, 2% salicylic, and 1% mandelic acids. By utilizing varying molecular weights, the pads aim to provide depth-targeted exfoliation across different layers of the skin. Dr. Suzan Obagi emphasized that the product is designed to simplify consistent, nightly exfoliation, which she identifies as a cornerstone of long-term skin health.

Clinical data shared by the company suggests measurable improvements over two months. After four weeks, 97% of participants reported smoother skin texture. By the eight-week mark, 90% noted improved smoothness, while 83% reported a reduction in breakouts and blemishes. Justin Giouzepis, Chief Marketing Officer at Obagi, noted that the expansion of the CLENZIderm M.D. franchise serves to bridge the gap between dermatologist-led treatments and consumer-accessible home care.

The peel pads are currently priced at $100 and are available through the official Obagi website, Amazon, and authorized medical providers. This launch follows a period of growth for the brand, which was recognized as the fastest-growing professional skincare line in the U.S. in 2024 according to Kline’s Global Professional Skin Care Series.